Stockscreener 앱 받기
10.97
8.75%
0.86
Tandem Diabetes Care Inc 주식(TNDM)의 최신 뉴스
Tandem Diabetes stock upgraded at Citi (TNDM:NASDAQ) - Seeking Alpha
Tandem Diabetes, iRhythm, agilon health, Fortrea, and 10x Genomics Shares Skyrocket and Plummet, What You Need To Know - Yahoo Finance
Citi Upgrades Tandem Diabetes Care to Neutral, Raises PT to $10.35 - AInvest
TNDM Q2 Deep Dive: Margin Pressures and Strategic Shifts Offset Sales Growth - ca.finance.yahoo.com
CFRA Maintains Hold Rating on Tandem Diabetes Care with $22 Price Target - AInvest
Tandem Diabetes Care's 2025 Q2 Earnings Call: Unpacking Contradictions in CMS Proposals, Pharmacy Strategies, and Renewal Growth - AInvest
CFRA slashes Tandem Diabetes Care stock price target on GLP-1 risks - Investing.com Canada
Tandem Diabetes Care: Pioneering the Future of Diabetes Management and a High-Conviction Growth Play in 2025 - AInvest
Tandem Diabetes Care Inc. Pipeline Analysis Report 2025: A Comprehensive Guide to the Company's Product Pipeline and Developmental Products - AInvest
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Benzinga
TNDM Stock Falls on Q2 Earnings Miss, Revenues Beat, Gross Margin Up - TradingView
Tandem Diabetes Care Inc. Forms Bullish Flag — Upside AheadScalable Portfolio Growth Suggestions Released - metal.it
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say - MSN
Tandem Diabetes projects $1B sales for 2025 as international growth, pharmacy channel, and product innovation drive outlook - MSN
Tandem Diabetes Care: Earnings Miss Confirms Bear CaseDowngrade To Sell (NASDAQ:TNDM) - Seeking Alpha
Insulin pump makers Tandem and Insulet post contrasting Q2 results - MSN
What does recent volatility data suggest for Tandem Diabetes Care Inc.Technical Analysis of Growth Stock Opportunities - Newser
Medtech Executives Monitor CMS Payment Proposal for Diabetes Technology - AInvest
How to build a custom watchlist for Tandem Diabetes Care Inc.Buy Zone Strategy with Pattern Recognition - Newser
Will Tandem Diabetes Care Inc. outperform the marketSmart Trend Analysis With Buy Point Cues - Newser
Chart based exit strategy for Tandem Diabetes Care Inc.Free Trade Ready Stock Watch for Short Term - Newser
How high can Tandem Diabetes Care Inc. stock goReal Time Screener for Growth Trades - Newser
Tandem Diabetes Care Inc. stock retracement – recovery analysisSafe Momentum Strategy With Trend Analysis - Newser
Tandem downgraded to Neutral at Piper Sandler on softer outlook - MSN
Tandem Diabetes Care Inc.’s volatility index tracking explainedWatchlist Summary for Active Day Traders - Newser
Tandem Diabetes Care issues voluntary correction for insulin pumps - Medical Buyer
Tandem Diabetes Care shares rise 4.31% intraday after UBS adjusts price target to $17. - AInvest
Tandem, Insulet monitoring CMS payment proposal for diabetes tech - MedTech Dive
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q2 2025 Earnings Call Transcript - Insider Monkey
Positive Outlook for Tandem Diabetes Care: Buy Rating Reaffirmed Amid Growth Catalysts and Strategic Opportunities - TipRanks
Tandem Diabetes Care’s Earnings Call Highlights Growth and Challenges - TipRanks
Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock - AOL.com
Tandem Diabetes Care Gains FDA Clearance for SteadiSet - TipRanks
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Beats Revenue Estimates - MSN
Tandem Diabetes Care (TNDM.O) Sees Sharp Intraday Decline: What’s Behind the Move? - AInvest
Tandem Diabetes Care issues voluntary device correction for certain insulin pumps - Reuters
Tandem insulin pump malfunction linked to 59 injuries - MedTech Dive
Tandem Diabetes' Stalled Momentum: Is the Market Overestimating Long-Term Resilience? - AInvest
TNDM.O Crashes 24.5%: What’s Behind the Sharp Drop? - AInvest
Tandem Diabetes Care price target lowered to $20 at TD Cowen on US sales concerns - Investing.com Canada
Tandem Diabetes announces medical device correction for t:slim X2 insulin pumps - TipRanks
TNDM.O Plummets 25%—What’s Behind the Sharp Move? - AInvest
UBS Adjusts Price Target on Tandem Diabetes Care to $17 From $20, Maintains Neutral Rating - MarketScreener
Earnings call transcript: Tandem Diabetes Care Q2 2025 misses EPS expectations - Investing.com Nigeria
Tandem Diabetes Care hits 7-year low on issuing voluntary device correction for certain insulin pumps - TradingView
Tandem Diabetes Plunges 21.2%: Can a Speaker Glitch Spell the End of a Diabetes Tech Giant? - AInvest
Truist Cuts Price Target on Tandem Diabetes Care to $14 From $15, Keeps Hold Rating - MarketScreener
Tandem Diabetes Issues Correction for Certain t:slim X2 Insulin Pumps - Medical Product Outsourcing
Tandem Diabetes Care drops after issuing voluntary device correction for certain insulin pumps - TradingView
Tandem Diabetes Care Inc issues voluntary medical device correction for select T:slim X2 insulin pumps - MarketScreener
Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps | TNDM Stock News - GuruFocus
Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps - Business Wire
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Tandem Diabetes shares fall 18.97% premarket after Q2 sales miss expectations. - AInvest
Tandem Diabetes Care Q2 2025: Revenue Surges but Profitability Concerns PersistNews and Statistics - IndexBox
Tandem Diabetes downgraded to Neutral from Overweight at Piper Sandler - TipRanks
Tandem Diabetes Care Hits Sales Milestone But Stays In The Red - Finimize
Tandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual Guidance - ADVFN Brasil
Earnings call transcript: Tandem Diabetes Care Q2 2025 misses EPS expectations By Investing.com - Investing.com South Africa
Piper Sandler downgrades Tandem Diabetes stock on weak domestic outlook By Investing.com - Investing.com Canada
Transcript : Tandem Diabetes Care, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Tandem Diabetes Care Reports Record Q2 2025 Sales - TipRanks
0.31%
0.67%
자본화:
|
볼륨(24시간):